Zasocitinib(NDI-034858, TAK-279) is a TYK2 inhibitor currently being investigated in a Phase IIb trial in moderate-to-severe plaque psoriasis.

 

Brand: BCM

 

Target: IL Receptor; Tyrosine Kinases

 

Signaling Pathways: Immunology/Inflammation; Tyrosine Kinase/Adaptors

 

In Vitro: NDI-034858 (compound I-908) (10 μM) demonstrates inhibitory activity against Tyk2 and JAK enzymes. It achieves this by targeting the Tyk2 JH1 domain and the JAK JH1 domain, resulting in inhibition rates of less than 50% for both enzymes.

 

pKa: 10.37±0.40(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

Isomeric SMILES: CNC1=CC(=NC2=C(C=NN12)C(=O)N[C@@H]3CC[C@H]3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5  

 

InChIKey: BWINBHTTZLVXGT-NVXWUHKLSA-N  

 

InChI: InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1

 

Attribute
[Chem Name]	N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide
[Synonym]	Zasocitinib; NDI-034858; TAK-279
[CAS No.]	2272904-53-5
[Formula]	C23H24N8O3
[Molecular]	460.49
[Form]	Solid Powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag